1 Introduction
==============

Dementia with Lewy bodies (DLB) is the second most common type of degenerative dementia after Alzheimer's disease (AD) \[[@B1]\]. Compared with AD, DLB is associated with poorer prognosis, shorter time to nursing home admission, higher care burden and higher healthcare costs \[[@B2]\]-\[[@B4]\]. However, cognitive and functional decline do not seem to differ between these two groups \[[@B5]\]. In addition to a more complex clinical picture of DLB that is characterized by visual hallucinations, motoric symptoms, sleep disorders and autonomic dysfunction, comorbidities may be crucial predictors of worse outcomes in DLB patients. Comorbid diseases significantly increase utilization of healthcare resources \[[@B2]\], predict key outcomes of acute hospital care in older people \[[@B6]\] and are associated with a higher risk of death after dementia diagnosis \[[@B7]\].

Little attention has been paid to research on comorbidities and risk factors of DLB. Previous studies showed that occurrence of depression \[[@B8]\],\[[@B9]\] and anxiety \[[@B10]\] is higher in DLB patients when compared with AD. Depression has been suggested as a risk factor for DLB \[[@B9]\] and was more likely to persist over time in DLB subjects compared with AD patients \[[@B11]\]. History of stroke and anxiety has been reported to occur more often in DLB patients than in healthy controls, but not in comparison with AD patients \[[@B9]\].

Correct assessment of risk factors and comorbidities is a central part of clinical management of DLB patients. Furthermore, understanding them may provide new insights into the underlying pathophysiology of DLB. In this study, capitalizing on two nationwide registries, we compared clinical risk factors and comorbidity profiles for AD and DLB in 9,795 subjects, including 634 patients with DLB. To the authors' best knowledge this is one of the largest published DLB cohorts.

2 Methods
=========

This study was performed by linking the Swedish Dementia Registry (SveDem) and the Swedish National Patient Registry. The personal identity number was used as the unique identifier for merging the two databases. Patients were followed-up until 31 December 2012.

2.1 Swedish Dementia Registry
-----------------------------

SveDem is a nationwide registry that includes newly diagnosed dementia patients from Sweden \[[@B12]\]. SveDem is a web-based quality registry, initiated in 2007, to improve the quality of diagnostics work-up, treatment and care of dementia across the country \[[@B13]\]. The majority of patients are registered through specialist care units (memory clinics) and the type of dementia is recorded as early-onset AD, late-onset AD, mixed AD, vascular dementia, DLB, frontotemporal dementia, Parkinson's disease with dementia, unspecified dementia or others.

At the end of 2012, 58 specialist units (93% of all in Sweden) and 659 primary care centers (60% of all in Sweden) were affiliated with SveDem. Using an estimated incidence rate of 20,000 patients that develop dementia in Sweden each year \[[@B14]\], the approximate coverage of incident dementia cases in SveDem in 2012 was 36%. However, the study population represents a census of all newly diagnosed dementia patients because all of those who referred to the registered centers were recruited.

This study population comprised only two subgroups, 634 individuals with DLB (DLB group) and 9,161 cases with AD (AD group), recruited during the years 2007 to 2012. Dementia was diagnosed according to the International Classification of Diseases (ICD) version 10 criteria \[[@B15]\]. In addition, McKeith criteria were used to diagnose DLB \[[@B16]\].

Information about age, sex, living conditions, medication profile, diagnosis of DLB and AD (ICD version 10 codes of G31.8 for DLB and G30.0 and G30.1 for AD), baseline Mini-Mental State Examination (MMSE) score \[[@B17]\] and date of referral for dementia work-up were obtained from the SveDem records.

2.2 Swedish National Patient Registry
-------------------------------------

The Swedish National Patient Registry is administered by the Swedish National Board of Health and Welfare, which covers inpatient care in Sweden to 1987 \[[@B18]\]. The doctor responsible for the patient determines the diagnoses in the registry based on clinical evaluations and laboratory assessments on that particular occasion of in-hospital care. Diagnoses were coded using the latest version of the ICD according to the year of registration.

At the time of discharge, the physician registers a main diagnosis and one or more secondary diagnoses if applicable for each patient. A similar procedure is also performed through all outpatient clinics and afterwards. The diagnostic codes are sent by the hospitals and outpatient clinics to the National Board of Health and Welfare. Later, one main diagnosis and up to seven secondary diagnoses are registered together with demographics and administrative information such as hospital, clinic, dates of admission and discharge, surgical procedures and patient characteristics including age, sex and place of residence. Data obtained from 2000 to 2012 were used for this study.

2.3 Comorbidity profile
-----------------------

In addition to the main chapters of the ICD version 10, another comparison was performed based on the comorbidity scoring of the ICD version 10 codes recommended by the Royal College of Surgeons called the Charlson Score \[[@B19]\]. The total Charlson score of comorbidities was calculated by counting the number of comorbidity categories without any preassigned weights \[[@B20]\]. Data on a selected list of neuropsychiatric diseases were also extracted from the Swedish National Patient Registry using the ICD version 10 codes as follows: depression (F32, F33), anxiety (F40, F41), behavioral disorders (F07, F10, F11, F12, F13, F14, F15, F16, F17, F18, F19, F53, F54, F59, F66, F68, F69, F98, R46), bipolar affective disorder (F31), sleep disorder (F51, G47), syncope (R55), ischemic stroke (I63, I64, I67, I69), cerebral hemorrhage (I60, I61, I62), epilepsy (G40), migraine (G43) and other types of headache (G44, R51). The time of registration was used to check whether the disease occurred before or after dementia diagnosis as well as to calculate the time intervals between the dates.

Since no information is available on the exact time when the symptoms started, we used the date of registration as the initial time point for dementia and the comorbidities. Therefore, if the date of registration for any of the comorbidities has been recorded prior to the date of registration in SveDem, we considered that comorbidity has occurred before dementia, and *vice versa*.

2.4 Statistical analysis
------------------------

The mean (standard deviation (SD)) and frequency percentage (%) were reported to describe quantitative and categorical variables. For univariate comparisons, the chi-square statistic and Fisher's exact test were used to compare the relative frequency of nominal variables (that is, sex, comorbidities) between the two study groups where appropriate. To compare the mean value of quantitative variables between the DLB and AD groups, either an independent-sample *t* test or a Mann--Whitney *U* test were used for normally or skewed distributions, respectively.

Further multivariate analysis was performed to adjust for the confounding effect of the baseline differences in age and sex between the DLB and AD groups. For this purpose, a binary logistic regression model was applied to evaluate the differences observed in the prevalence of different comorbidities between the DLB and AD groups adjusted for the baseline confounders. Afterwards, the adjusted odds ratio (OR) and its corresponding 95% confidence interval (CI) for each comorbidity were calculated. For the comorbidities that occurred before the date of referral for dementia, type of dementia (DLB vs. AD) was considered the dependent variable. If the comorbid event happened after dementia diagnosis, the comorbidity was defined as the dependent variable and the type of dementia as a predictor in the multivariate model. In all analytical procedures, two-tailed *P* \< 0.05 was considered to show statistically significant difference. Data were analyzed using SPSS software version 22 (IBM Co., Chicago, IL USA).

2.5 Ethical issues
------------------

The regional Ethical Committee of Stockholm approved data collection (Drn. 2013/147-31/2), as well as the merging and the analytical procedures performed in this study. The patients were informed orally and in writing about SveDem and could decline participation. Data were coded and anonymized before statistical analysis.

3 Results
=========

3.1 Baseline characteristics
----------------------------

A total number of 634 individuals with DLB and 9,161 AD patients were recruited. The DLB group consisted of 382 (60.3%) males and 252 (39.7%) females with a mean age of 76.5 (SD = 7.1) years*.* The AD group comprised 3,188 (34.8%) males and 5,973 (65.2%) females with a mean age of 77.6 (SD = 8.3) years at the time of dementia diagnosis. Results of the Pearson chi-square test and the independent-samples *t* test revealed that there were significantly more males (*P* \< 0.001) and fewer old patients (*P* \< 0.001) in the DLB group. Other baseline, demographic and medication characteristics of the two study groups are presented and compared in Table [1](#T1){ref-type="table"}. The mean of the baseline MMSE score was quite similar in the DLB (21.4 (SD = 5.0)) and AD (21.5 (SD = 5.0)) groups (*P* = 0.593). However, in the DLB group the proportion of patients in nursing homes was larger than that in the AD group (11.8% vs. 5.6%, *P* \< 0.001).

###### 

Baseline, diagnostic and medication characteristics of the two study groups: cases suffering from dementia with Lewy bodies versus Alzheimer's disease patients

  **Characteristic**                       **Dementia with Lewy bodies**   **Alzheimer's disease**    ***P*value**
  --------------------------------------- ------------------------------- ------------------------- ----------------
  Gender                                                                                             **\<0.001**^a^
    Female                                          252 (39.7%)                 5973 (65.2%)        
    Male                                            382 (60.3%)                 3188 (34.8%)        
  Age (years)                                       76.5 (7.1)                   77.6 (8.3)          **\<0.001**^b^
  MMSE score                                        21.4 (5.0)                   21.5 (5.0)             0.593^b^
  Body mass index (kg/m^2^)                         24.4 (4.1)                   24.3 (4.1)             0.565^b^
  Living place                                                                                       **\<0.001**^a^
    Own house                                       559 (88.2%)                 8627 (94.4%)        
    Nursing home                                    75 (11.8%)                   512 (5.6%)         
  Co-resident                                                                                        **\<0.001**^a^
    Yes                                             218 (36.0%)                 3879 (44.0%)        
    No                                              387 (64.0%)                 4938 (56.0%)        
  Medication (at the time of diagnosis)                                                             
    Cholinesterase inhibitors                       465 (73.6%)                 6598 (72.7%)            0.272^a^
    NMDA antagonist                                 95 (15.0%)                   895 (9.9%)          **\<0.001**^a^
    Antidepressants                                 220 (34.8%)                 2382 (26.3%)         **\<0.001**^a^
    Antipsychotics                                  103 (16.3%)                  447 (4.9%)          **\<0.001**^a^
    Anxiolytics                                     84 (13.3%)                   747 (8.2%)          **\<0.001**^a^
    Hypnotics                                       106 (16.8%)                 1292 (14.2%)            0.065^a^
    Cardiovascular drugs                            365 (57.8%)                 4825 (53.2%)            0.054^a^
  Total number of drugs                              4.7 (3.0)                    3.7 (2.9)          **\<0.001**^b^

Data presented as number (%) or mean (standard deviation). Statistically significant differences (*P* \< 0.05) in bold. MMSE, Mini-Mental State Examination; NMDA, *N*-methyl [d]{.smallcaps}-aspartate. ^a^Pearson chi-square statistic. ^b^Independent-sample *t* test.

DLB patients were under treatment with a significantly higher number of medications (4.7 (SD = 3.0)) compared with the AD group (3.7 (SD = 2.9)). A multivariate Poisson regression model showed that DLB patients received a higher number of drugs (*B* = 0.268 (95% CI = 0.230 to 0.307), *P* \< 0.001) after adjustment for sex and age. While a similar proportion of patients were treated with cholinesterase inhibitors in both the DLB (73.6%) and AD (72.7%) groups (*P* = 0.272), *N*-methyl [d]{.smallcaps}-aspartate antagonists (15.0% vs. 9.9%), antidepressants (34.8% vs. 26.3%), antipsychotics (16.3% vs. 4.9%) and anxiolytics (13.3% vs. 8.2%) were significantly more often prescribed among the DLB group.

3.2 International Classification of Diseases version 10 chapters
----------------------------------------------------------------

Table [2](#T2){ref-type="table"} summarizes the comorbidity profile of the DLB and AD patients based on the chapters of the ICD version 10 coding system. 'Mental and behavioral disorders' (66.1%) and 'diseases of the eye and adnexa' (57.9%) were the most common categories recorded for the DLB group apart from the 'diseases of the nervous system'; while among the AD patients 'diseases of the eye and adnexa' (47.9%), 'diseases of the musculoskeletal system and connective tissue' (40.7%) and 'diseases of the circulatory system' (40.3%) were most commonly recorded as comorbid conditions. 'Mental and behavioral disorders', 'diseases of the nervous system' , 'diseases of the eye and adnexa' , diseases of the 'circulatory' , 'respiratory' , 'digestive' and 'genitourinary' systems and the 'diseases of the skin and subcutaneous tissue' occurred more commonly in the DLB group based on the univariate comparisons.

###### 

Comorbidity profile of the patients with dementia with Lewy bodies versus Alzheimer's disease patients based on the chapters of the International Statistical Classification of Diseases and Related Health Problems, 10th Revision

   **Chapter**   **Blocks**  **Title**                                                                                               **DLB**        **AD**          **Unadjusted**        ***P*value**^**a**^        **Adjusted**         ***P*value**^**b**^
  ------------- ------------ ----------------------------------------------------------------------------------------------------- ------------ -------------- ------------------------- --------------------- ------------------------- ---------------------
        I        A00 to B99  Certain infectious and parasitic diseases                                                              87 (13.7)    1,064 (11.6)     1.21 (0.96 to 1.53)            0.111            1.25 (0.98 to 1.59)            0.069
       II        C00 to D48  Neoplasms                                                                                              203 (32.0)   2,733 (29.8)     1.11 (0.93 to 1.32)            0.245            1.06 (0.88 to 1.27)            0.541
       III       D50 to D89  Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism     29 (4.6)     433 (4.7)       0.97 (0.66 to 1.42)            0.861            1.01 (0.68 to 1.49)            0.976
       IV        E00 to E90  Endocrine, nutritional and metabolic diseases                                                          79 (12.5)    1,088 (11.9)     1.06 (0.83 to 1.35)            0.661            1.16 (0.90 to 1.49)            0.239
        V        F00 to F99  Mental and behavioral disorders                                                                        419 (66.1)   3,543 (38.7)   **3.09 (2.61 to 3.66)**       **\<0.001**       **3.14 (2.63 to 3.75)**       **\<0.001**
       VI        G00 to G99  Diseases of the nervous system                                                                         558 (88.0)   6,508 (71.0)   **2.99 (2.34 to 3.82)**       **\<0.001**       **2.78 (2.15 to 3.58)**       **\<0.001**
       VII       H00 to H59  Diseases of the eye and adnexa                                                                         367 (57.9)   4,390 (47.9)   **1.49 (1.27 to 1.76)**       **\<0.001**       **1.69 (1.42 to 2.01)**       **\<0.001**
      VIII       H60 to H95  Diseases of the ear and mastoid process                                                                96 (15.1)    1,462 (16.0)     0.94 (0.75 to 1.18)            0.586            0.97 (0.77 to 1.22)            0.810
       IX        I00 to I99  Diseases of the circulatory system                                                                     293 (46.2)   3,693 (40.3)   **1.27 (1.08 to 1.49)**        **0.003**        **1.29 (1.08 to 1.52)**        **0.004**
        X        J00 to J99  Diseases of the respiratory system                                                                     146 (23.0)   1,663 (18.2)   **1.35 (1.11 to 1.63)**        **0.002**        **1.30 (1.06 to 1.59)**        **0.010**
       XI        K00 to K93  Diseases of the digestive system                                                                       237 (37.4)   2,966 (32.4)   **1.25 (1.05 to 1.47)**        **0.009**          1.17 (0.98 to 1.39)            0.082
       XII       L00 to L99  Diseases of the skin and subcutaneous tissue                                                           155 (24.4)   1,918 (20.9)   **1.22 (1.01 to 1.47)**        **0.036**        **1.27 (1.05 to 1.54)**        **0.016**
      XIII       M00 to M99  Diseases of the musculoskeletal system and connective tissue                                           273 (43.1)   3,732 (40.7)     1.10 (0.93 to 1.29)            0.250          **1.19 (1.01 to 1.41)**        **0.040**
       XIV       N00 to N99  Diseases of the genitourinary system                                                                   233 (36.8)   2,984 (32.6)   **1.20 (1.02 to 1.42)**        **0.030**        **1.24 (1.04 to 1.47)**        **0.015**
       XV        O00 to O99  Pregnancy, childbirth and the puerperium                                                                1 (0.2)       2 (0.0)                --                      --                      --                      --
       XVI       P00 to P96  Certain conditions originating in the perinatal period                                                     0             0                   --                      --                      --                      --
      XVII       Q00 to Q99  Congenital malformations, deformations and chromosomal abnormalities                                    5 (0.8)       57 (0.6)       1.27 (0.51 to 3.18)            0.609            1.55 (0.61 to 3.98)            0.358
      XVIII      R00 to R99  Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified                460 (72.6)   5,896 (64.4)   **1.46 (1.22 to 1.75)**       **\<0.001**       **1.44 (1.19 to 1.73)**       **\<0.001**
       XIX       S00 to T98  Injury, poisoning and certain other consequences of external causes                                    369 (58.2)   4,679 (51.1)   **1.33 (1.13 to 1.57)**        **0.001**        **1.54 (1.30 to 1.83)**       **\<0.001**
       XX        V01 to Y98  External causes of morbidity and mortality                                                                 0          1 (0.0)                --                      --                      --                      --
       XXI       Z00 to Z99  Factors influencing health status and contact with health services                                     523 (82.5)   6,718 (73.3)   **1.71 (1.39 to 2.11)**       **\<0.001**       **1.73 (1.39 to 2.16)**       **\<0.001**

Adjustment is made for age, sex, and Mini-Mental State Examination score. The AD group is considered the reference group. Statistically significant ORs (*P \<* 0.05) in bold. AD, Alzheimer's disease; CI, confidence interval; DLB, dementia with Lewy bodies; OR, odds ratio. ^a^Chi-square statistics. ^b^Binary logistic regression model.

As shown in Table [2](#T2){ref-type="table"}, all univariate significant differences remained statistically significant after multivariate adjustment except for the 'diseases of the digestive system'. Moreover, DLB patients suffered more from the 'diseases of the musculoskeletal system and connective tissue' after adjustment for age and sex (adjusted OR = 1.19 (95% CI = 1.01 to 1.41)). The greatest between-group differences in the ICD version 10 disease categories were observed in 'mental and behavioral disorders' (66.1% vs. 38.7%, adjusted OR = 3.14 (95% CI = 2.63 to 3.75)), 'diseases of the nervous system' (88.0% vs. 71.0%, adjusted OR = 2.78 (95% CI = 2.15 to 3.58)) and 'diseases of the eye and adnexa' (57.9% vs. 47.9%, adjusted OR = 1.69 (95% CI = 1.42 to 2.01)), all of which were more common in the DLB group.

Further subgroup analysis was performed to assess how patients' gender, level of cognition and living place might affect the differences in the comorbidity profile between the DLB and AD groups. As summarized in Table [3](#T3){ref-type="table"}, some comorbidity categories such as 'mental and behavioral disorders' and 'diseases of the nervous system' were significantly more common in the DLB group among all of the subgroups regarding gender, cognition and living place (all *P* \< 0.05). On the other hand, 'diseases of the circulatory system' was significantly more prevalent in the DLB patients who were female (46.8% vs. 38.6%, *P* = 0.009), had MMSE \< 22 (49.6% vs. 39.1%, *P* = 0.001) and live in their own house (46.3% vs. 40.2%, *P* = 0.005).

###### 

**Comorbidity profile of patients with dementia with Lewy bodies (*n***  **= 634) versus Alzheimer's disease patients (*n***  **= 9,161) within different subgroups regarding gender, cognitive level at the time of diagnosis and living place using the chapters of the International Statistical Classification of Diseases and Related Health Problems, 10th Revision**

  **Title**                                                                                             **Gender**    **DLB (%)**   **AD (%)**    ***P*value**   **Cognition**   **DLB (%)**   **AD (%)**    ***P*value**   **Living place**   **DLB (%)**   **AD (%)**    ***P*value**
  ----------------------------------------------------------------------------------------------------- ------------ ------------- ------------- -------------- --------------- ------------- ------------- -------------- ------------------ ------------- ------------- --------------
  Certain infectious and parasitic diseases                                                             Male             14.9          12.5          0.183         MMSE ≥ 22        16.3          11.2        **0.005**        Own house          14.3          11.4        **0.038**
  Female                                                                                                11.9             11.1          0.703       MMSE \< 22        11.9           12.2          0.855      Nursing home         9.3             15.0          0.188     
  Neoplasms                                                                                             Male             35.6          33.8          0.494         MMSE ≥ 22        32.8          31.6          0.652          Own house          32.4          30.1          0.259
  Female                                                                                                26.6             27.7          0.701       MMSE \< 22        31.9           27.9          0.169      Nursing home         29.3            25.4          0.467     
  Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism   Male              5.2           4.8          0.687         MMSE ≥ 22         3.6           4.5          0.447          Own house           4.7           4.6          0.967
  Female                                                                                                3.6               4.7          0.403       MMSE \< 22         5.9            4.8          0.414      Nursing home         4.0              6.8          0.457     
  Endocrine, nutritional and metabolic diseases                                                         Male             12.8          10.9          0.262         MMSE ≥ 22        10.5          11.7          0.526          Own house          12.3          11.8          0.700
  Female                                                                                                11.9             12.4          0.819       MMSE \< 22        15.9           11.8        **0.046**    Nursing home         13.3            13.5          0.973     
  Mental and behavioral disorders                                                                       Male             67.3          37.4       **\<0.001**      MMSE ≥ 22        65.7          40.8       **\<0.001**       Own house          65.5          38.8       **\<0.001**
  Female                                                                                                64.3             39.3       **\<0.001**    MMSE \< 22        66.7           36.0       **\<0.001**   Nursing home         70.7            36.5       **\<0.001**  
  Diseases of the nervous system                                                                        Male             91.4          72.8       **\<0.001**      MMSE ≥ 22        89.5          75.5       **\<0.001**       Own house          88.7          72.2       **\<0.001**
  Female                                                                                                82.9             70.1       **\<0.001**    MMSE \< 22        86.3           66.8       **\<0.001**   Nursing home         82.7            52.3       **\<0.001**  
  Diseases of the eye and adnexa                                                                        Male             56.5          44.2       **\<0.001**      MMSE ≥ 22        60.2          49.0       **\<0.001**       Own house          58.3          47.7       **\<0.001**
  Female                                                                                                59.9             49.9        **0.002**     MMSE \< 22        55.6           47.0        **0.007**    Nursing home         54.7            52.0          0.660     
  Diseases of the ear and mastoid process                                                               Male             15.4          17.2          0.383         MMSE ≥ 22        17.5          17.1          0.857          Own house          15.7          16.2          0.790
  Female                                                                                                14.7             15.3          0.794       MMSE \< 22        14.1           14.6          0.819      Nursing home         10.7            12.9          0.588     
  Diseases of the circulatory system                                                                    Male             45.8          43.5          0.391         MMSE ≥ 22        43.7          40.8          0.296          Own house          46.3          40.2        **0.005**
  Female                                                                                                46.8             38.6        **0.009**     MMSE \< 22        49.6           39.1        **0.001**    Nursing home         45.3            41.2          0.499     
  Diseases of the respiratory system                                                                    Male             27.7          20.5        **0.001**       MMSE ≥ 22        22.0          17.6        **0.043**        Own house          22.9          18.0        **0.004**
  Female                                                                                                15.9             16.9          0.677       MMSE \< 22        24.4           18.6        **0.018**    Nursing home         24.0            20.1          0.438     
  Diseases of the digestive system                                                                      Male             41.6          37.0          0.079         MMSE ≥ 22        36.7          34.3          0.357          Own house          37.7          32.7        **0.013**
  Female                                                                                                31.0             29.9          0.721       MMSE \< 22        38.9           30.3        **0.003**    Nursing home         34.7            27.9          0.229     
  Diseases of the skin and subcutaneous tissue                                                          Male             24.3          20.2          0.057         MMSE ≥ 22        25.3          22.5          0.230          Own house          24.7          21.1        **0.043**
  Female                                                                                                24.6             21.3          0.217       MMSE \< 22        24.1           19.3          0.056      Nursing home         22.7            18.6          0.397     
  Diseases of the musculoskeletal system and connective tissue                                          Male             39.8          36.1          0.157         MMSE ≥ 22        41.3          42.9          0.555          Own house          42.9          41.0          0.371
  Female                                                                                                48.0             43.2          0.132       MMSE \< 22        45.6           38.5        **0.022**    Nursing home         44.0            37.5          0.280     
  Diseases of the genitourinary system                                                                  Male             36.4          32.1          0.093         MMSE ≥ 22        38.0          33.6          0.108          Own house          38.3          32.6        **0.005**
  Female                                                                                                37.3             32.8          0.138       MMSE \< 22        35.6           31.1          0.132      Nursing home         25.3            32.6          0.205     
  Pregnancy, childbirth and the puerperium                                                              Male              --            --             --          MMSE ≥ 22         0.3            0           0.062          Own house           0.2            0           0.061
  Female                                                                                                0.4                0           0.117       MMSE \< 22          0             0.1            1        Nursing home          0               0.4            1       
  Certain conditions originating in the perinatal period                                                Male               0             0             --          MMSE ≥ 22          0             0             --           Own house            0             0             --
  Female                                                                                                0                  0            --         MMSE \< 22          0              0            --        Nursing home          0                0            --       
  Congenital malformations, deformations and chromosomal abnormalities                                  Male              1.0           0.6          0.300         MMSE ≥ 22         0.9           0.6          0.464          Own house           0.7           0.5          0.545
  Female                                                                                                0.4               0.6            1         MMSE \< 22         0.7            0.4          0.349      Nursing home         1.3              2.1            1       
  Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified               Male             72.8          66.9        **0.020**       MMSE ≥ 22        74.1          67.2        **0.010**        Own house          72.3          64.5       **\<0.001**
  Female                                                                                                72.2             63.0        **0.003**     MMSE \< 22        71.5           61.3        **0.001**    Nursing home         74.7            62.7        **0.043**   
  Injury, poisoning and certain other consequences of external causes                                   Male             50.8          45.1        **0.034**       MMSE ≥ 22        59.6          49.2       **\<0.001**       Own house          58.3          50.2       **\<0.001**
  Female                                                                                                69.4             54.3       **\<0.001**    MMSE \< 22        56.7           53.5          0.312      Nursing home         57.3            64.8          0.206     
  External causes of morbidity and mortality                                                            Male               0             0             --          MMSE ≥ 22          0             0             --           Own house            0             0             --
  Female                                                                                                0                  0            --         MMSE \< 22          0              0            --        Nursing home          0                0            --       
  Factors influencing health status and contact with health services                                    Male             81.4          73.0       **\<0.001**      MMSE ≥ 22        84.3          76.8        **0.001**        Own house          83.2          73.8       **\<0.001**
  Female                                                                                                84.1             73.5       **\<0.001**    MMSE \< 22        81.1           69.8       **\<0.001**   Nursing home         77.3            65.8        **0.047**   

Statistically significant differences (*P* \< 0.05) in bold. Univariate comparisons were performed using either the chi-square or Fisher's exact test wherever appropriate. AD, Alzheimer's disease; DLB, dementia with Lewy bodies; MMSE, Mini-Mental State Examination.

Although 'diseases of the respiratory system' was more commonly recorded in the DLB patients with both MMSE ≥ 22 (*P* = 0.043) and MMSE \< 22 (*P* = 0.018), with regard to gender and living place the difference was significant only among the males (27.7% vs. 20.5%, *P* = 0.001) and those who live in their own houses (22.9% vs. 18.0%, *P* = 0.004). Furthermore, 'diseases of the digestive system' (38.9% vs. 30.3%, *P* = 0.003) and 'diseases of the musculoskeletal system and connective tissue' (45.6% vs. 38.5%, *P* = 0.022) were significantly higher in the DLB group compared with the AD group only among the subgroup with MMSE \< 22 at the time of diagnosis.

3.3 Charlson comorbidity scoring
--------------------------------

Comorbidity profiles of the DLB and AD patients using the Royal College of Surgeons Charlson categorization of the ICD version 10 codes are presented in Table [4](#T4){ref-type="table"}. Cerebrovascular diseases were more common in the DLB group after adjustment for age and sex (16.2% vs. 10.0%, adjusted OR = 1.74 (95% CI = 1.38 to 2.19)). As illustrated in Figure [1](#F1){ref-type="fig"}, 12.7% of the AD patients had a zero score according to the Charlson scoring of the comorbidities, while only 3.3% of the DLB patients showed this condition. The proportion of individuals with one, two and three or more comorbidity categories of Charlson scoring was higher in the DLB group (*P* \< 0.001). Moreover, DLB patients had a significantly higher mean for the total Charlson score (1.52 (SD = 0.85) vs. 1.33 (SD = 0.89)). This difference remained significant even after multivariate adjustment (OR = 1.22 (95% CI = 1.12 to 1.33)).

###### 

Comorbidity profile of the patients with dementia with Lewy bodies versus Alzheimer's disease patients based on the Royal College of Surgeons Charlson Score indicating International Classification of Disease, 10th revision codes for 14 disease categories

  **Disease category**             **DLB**       **AD**          **Unadjusted**        ***P*value**^**a**^        **Adjusted**         ***P*value**^**b**^
  ----------------------------- ------------- ------------- ------------------------- --------------------- ------------------------- ---------------------
  Myocardial infarction           34 (5.4)      532 (5.8)      0.92 (0.64 to 1.31)            0.643            0.85 (0.59 to 1.22)            0.372
  Congestive cardiac failure      38 (6.0)      458 (5.0)      1.21 (0.86 to 1.70)            0.270            1.21 (0.85 to 1.73)            0.282
  Peripheral vascular disease     15 (2.4)      271 (3.0)      0.79 (0.47 to 1.34)            0.392            0.77 (0.45 to 1.31)            0.335
  Cerebrovascular disease        103 (16.2)    912 (10.0)    **1.75 (1.40 to 2.19)**       **\<0.001**       **1.74 (1.38 to 2.19)**       **\<0.001**
  Chronic pulmonary disease       27 (4.3)      480 (5.2)      0.80 (0.54 to 1.20)            0.281            0.88 (0.59 to 1.31)            0.525
  Rheumatological disease         12 (1.9)      286 (3.1)      0.60 (0.33 to 1.07)            0.081            0.64 (0.35 to 1.19)            0.160
  Liver disease                    4 (0.6)      48 (0.5)       1.20 (0.43 to 3.35)            0.578            1.13 (0.40 to 3.19)            0.818
  Diabetes mellitus               26 (4.1)      481 (5.3)      0.77 (0.52 to 1.15)            0.206            0.73 (0.48 to 1.11)            0.145
  Hemiplegia or paraplegia            0         19 (0.2)               --                     0.631                    --                     0.998
  Renal disease                   11 (1.7)      98 (1.1)       1.63 (0.87 to 3.06)            0.123            1.57 (0.83 to 2.97)            0.167
  Any malignancy                  94 (14.8)    1283 (14.0)     1.07 (0.85 to 1.34)            0.565            0.96 (0.75 to 1.21)            0.707
  Metastatic solid tumor           2 (0.3)      74 (0.8)       0.39 (0.09 to 1.59)            0.239            0.42 (0.10 to 1.74)            0.235
  AIDS/HIV infection                  0          1 (0.0)               --                      --                      --                      --
  Total Charlson score           1.52 (0.85)   1.33 (0.89)   **1.25 (1.15 to 1.36)**       **\<0.001**       **1.22 (1.12 to 1.33)**       **\<0.001**

Data presented as mean (standard deviation). Adjustment is made for age, sex, and Mini-Mental State Examination score. The AD group is considered the reference group. The dementia category of the original Charlson scoring is not reported here because the whole study population is dementia patients in our study. Statistically significant ORs (*P* \< 0.05) in bold. AD, Alzheimer's disease; CI, confidence interval; DLB, dementia with Lewy bodies; OR, odds ratio. ^a^Chi-square statistics. ^b^Binary logistic regression model.

![**Frequency of dementia with Lewy bodies and Alzheimer's disease in patients with different number of comorbidities.** Frequency of dementia with Lewy bodies (DLB, *n* = 634) and Alzheimer's disease (AD, *n* = 9,161) in patients with different number of comorbidities based on the categories of the Royal College of Surgeons Charlson Score identified on the International Classification of Disease, 10th revision codes.](s13195-014-0065-2-1){#F1}

3.4 Neuropsychiatric comorbidities
----------------------------------

Considering the date of registration in SveDem and the Swedish National Patient Registry, occurrence of the selected neuropsychiatric comorbidities was determined as either before or after dementia diagnosis. As presented in Table [5](#T5){ref-type="table"}, depression was the most common neuropsychiatric comorbidity before the diagnosis of dementia in both groups (6.0% in DLB and 3.0% in AD). Among strokes, cerebral infarction was more common in the DLB group than in the AD group, while the frequency of cerebral hemorrhages did not differ between the AD and DLB groups. According to univariate comparisons (Table [5](#T5){ref-type="table"}), depression (*P* \< 0.001), behavioral disorders (*P* = 0.012), stroke (*P* = 0.002) and migraine (*P* = 0.028) were all more frequent in individuals with DLB compared with the AD group. However, the other types of headache were not significantly different between the two groups (3.2% in DLB and 3.4% in AD, OR = 0.92 (95% CI = 0.58 to 1.45), *P* = 0.713).

###### 

Occurrence and timing for different neuropsychiatric comorbidities in patients with dementia with Lewy bodies versus Alzheimer's disease patients

  **Comorbidity**                **Dementia with Lewy bodies**   **Alzheimer's disease**   ***P*value**^**a**^
  ----------------------------- ------------------------------- ------------------------- ---------------------
  Depression                                                                                   **\<0.001**
    None                                  587 (92.7)                  8,736 (95.5)        
    Before dementia diagnosis              38 (6.0)                     277 (3.0)         
    After dementia diagnosis                8 (1.3)                     130 (1.4)         
  Anxiety                                                                                         0.508
    None                                  612 (96.7)                  8,905 (97.4)        
    Before dementia diagnosis              16 (2.5)                     172 (1.9)         
    After dementia diagnosis                5 (0.8)                     66 (0.7)          
  Behavioral disorders                                                                          **0.012**
    None                                  612 (96.7)                  8,964 (98.0)        
    Before dementia diagnosis               9 (1.4)                     107 (1.2)         
    After dementia diagnosis               12 (1.9)                     72 (0.8)          
  Bipolar affective disorder                                                                      0.258
    None                                  628 (99.2)                  9,100 (99.5)        
    Before dementia diagnosis               5 (0.8)                     36 (0.4)          
    After dementia diagnosis                   0                         7 (0.1)          
  Sleep disorders                                                                                 0.093
    None                                  616 (97.3)                  9,001 (98.4)        
    Before dementia diagnosis              14 (2.2)                     116 (1.3)         
    After dementia diagnosis                3 (0.5)                     26 (0.3)          
  Syncope                                                                                         0.472
    None                                  587 (92.7)                  8,486 (92.8)        
    Before dementia diagnosis              35 (5.5)                     443 (4.8)         
    After dementia diagnosis               11 (1.7)                     214 (2.3)         
  Stroke                                                                                        **0.002**
    None                                  580 (91.6)                  8,665 (94.8)        
    Before dementia diagnosis              28 (4.4)                     277 (3.0)         
    After dementia diagnosis               25 (3.9)                     201 (2.2)         
  Cerebral hemorrhage                                                                             0.709
    None                                  623 (98.4)                  9,015 (98.6)        
    Before dementia diagnosis               6 (0.9)                     62 (0.7)          
    After dementia diagnosis                4 (0.6)                     66 (0.7)          
  Epilepsy                                                                                        0.291
    None                                  622 (98.3)                  9,022 (98.7)        
    Before dementia diagnosis               8 (1.3)                     66 (0.7)          
    After dementia diagnosis                3 (0.4)                     55 (0.6)          
  Migraine                                                                                      **0.028**
    None                                  627 (99.1)                  9,113 (99.7)        
    Before dementia diagnosis               6 (0.9)                     28 (0.3)          
    After dementia diagnosis                   0                         2 (0.0)          

Data presented as number (%). Statistically significant differences (*P* \< 0.05) in bold. ^a^Pearson chi-square statistics.

Figure [2](#F2){ref-type="fig"} illustrates the forest plots of adjusted OR for each neuropsychiatric comorbidity in DLB with AD as the reference group. With respect to the timing of the events, depression (adjusted OR = 2.12 (95% CI = 1.49 to 3.03)) and migraine (adjusted OR = 3.65 (95% CI = 1.48 to 9.0)) were more commonly recorded before the diagnosis of dementia in the DLB group (Figure [2](#F2){ref-type="fig"}B). As shown in Figure [2](#F2){ref-type="fig"}C, ischemic stroke (adjusted OR = 1.89 (95% CI = 1.21 to 2.96)) was the only significant comorbid condition that was more likely to happen among the DLB patients compared with the AD population after the onset of dementia.

![**Forest plot for odds ratios of the selected list of neuropsychiatric comorbidities for dementia with Lewy bodies compared with Alzheimer's disease as the reference group in different three conditions. (A)** Overall assessment (regardless of the timing). **(B)** Comorbidities recorded prior to the diagnosis of dementia as a risk factor for type of dementia (DLB vs. AD). **(C)** Type of dementia (DLB vs. AD) as a risk factor for comorbidities occurred after the diagnosis of dementia. AD, Alzheimer's disease; CI, confidence interval; DLB, dementia with Lewy bodies.](s13195-014-0065-2-2){#F2}

Further subgroup analysis was performed regarding gender, cognitive level and living place. As summarized in Table [6](#T6){ref-type="table"}, depression and stroke were more common in the DLB group compared with AD patients among both males and females (all *P* \< 0.05), whereas the higher prevalence of anxiety in DLB patients was statistically significant only among the males (3.4% vs. 1.8%, *P* = 0.031). With respect to level of cognition, depression, stroke and migraine were significantly more common in DLB patients compared with the AD group only among those with MMSE \< 22 (all *P* \< 0.05). Depression, sleep disorders and stroke were more commonly occurred in the DLB patients compared with the AD group among those who were living in their own house (all *P* \< 0.05), while migraine was more prevalent in DLB patients who lived in nursing homes (2.7% vs. 0.2%, *P* = 0.045).

###### 

**Frequency of different neuropsychiatric comorbidities in patients with dementia with Lewy bodies (*n***  **= 634) versus Alzheimer's disease patients (*n***  **= 9,161) within different subgroups regarding gender, cognitive level at the time of diagnosis and living place using the chapters of the International Statistical Classification of Diseases and Related Health Problems, 10th Revision**

  **Title**                      **Gender**   **DLB (%)**   **AD (%)**   ***P*value**   **Cognition**   **DLB (%)**   **AD (%)**   ***P*value**   **Living place**   **DLB (%)**   **AD (%)**   ***P*value**
  ----------------------------- ------------ ------------- ------------ -------------- --------------- ------------- ------------ -------------- ------------------ ------------- ------------ --------------
  Depression                        Male          6.3          3.8        **0.020**       MMSE ≥ 22         6.3          5.2          0.350          Own house           7.0          4.5        **0.006**
  Female                            8.7           4.8       **0.005**     MMSE \< 22         7.4            3.5       **0.001**    Nursing home         9.3              3.9         0.068     
  Anxiety                           Male          3.4          1.8        **0.031**       MMSE ≥ 22         3.3          2.7          0.464          Own house           3.2          2.6          0.372
  Female                            3.2           3.0         0.901       MMSE \< 22         3.3            2.7         0.528      Nursing home         4.0              2.8         0.469     
  Behavioral disorders              Male          3.4          2.6          0.381         MMSE ≥ 22         2.4          1.9          0.471          Own house           2.9          1.8          0.079
  Female                            3.2           1.6         0.071       MMSE \< 22         3.7            2.0         0.062      Nursing home         6.7              4.1         0.362     
  Bipolar affective disorders       Male          0.5          0.5          0.702         MMSE ≥ 22         0.6          0.5          0.689          Own house           0.9          0.4          0.185
  Female                            1.2           0.5         0.129       MMSE \< 22         1.1            0.4         0.105      Nursing home          0               1.0           1       
  Sleep disorders                   Male          3.9          2.5          0.094         MMSE ≥ 22         2.7          2.0          0.339          Own house           2.7          1.6        **0.040**
  Female                            0.8           1.1           1         MMSE \< 22         2.2            1.1         0.124      Nursing home         2.7              1.4         0.325     
  Syncope                           Male          7.1          6.7          0.789         MMSE ≥ 22         6.9          7.4          0.782          Own house           7.5          7.2          0.740
  Female                            7.5           7.4         0.950       MMSE \< 22         7.8            6.9         0.579      Nursing home         5.3              7.7         0.471     
  Stroke                            Male          8.7          6.0        **0.043**       MMSE ≥ 22         6.9          5.3          0.193          Own house           8.4          5.1        **0.001**
  Female                            7.9           4.8       **0.025**     MMSE \< 22         9.3            5.0       **0.002**    Nursing home         8.0              7.1         0.772     
  Cerebral hemorrhage               Male          1.8          1.6          0.732         MMSE ≥ 22         1.2          1.2          0.547          Own house           1.8          1.4          0.410
  Female                            1.2           1.3           1         MMSE \< 22         1.9            1.7         0.807      Nursing home          0               1.8         0.613     
  Epilepsy                          Male          1.6          1.5          0.958         MMSE ≥ 22         1.2          1.3            1            Own house           1.8          1.3          0.287
  Female                            2.0           1.2         0.242       MMSE \< 22         2.2            1.2         0.165      Nursing home         1.3              2.4           1       
  Migraine                          Male          0.5          0.2          0.249         MMSE ≥ 22         0.9          0.4          0.165          Own house           0.7          0.3          0.138
  Female                            1.6           0.4         0.580       MMSE \< 22         1.1            0.2       **0.034**    Nursing home         2.7              0.2       **0.045**   

Univariate comparisons were performed using either the chi-square or Fisher's exact test wherever appropriate. Statistically significant differences (*P* \< 0.05) in bold. AD, Alzheimer's disease; DLB, dementia with Lewy bodies; MMSE, Mini-Mental State Examination.

4 Discussion
============

In this study we investigated selected risk factors and comorbidities in patients suffering from DLB in comparison with AD. There were more males in the DLB group, which is in line with previous studies \[[@B21]\]. At the time when dementia diagnosis was set, DLB patients were younger, and, despite similar level of cognitive impairment, lived more frequently in nursing homes and received more psychiatric medication and a higher total number of drugs. This indicates a worse health profile at the time when dementia was diagnosed and suggests that DLB patients may have been affected by a larger number of diseases before they developed dementia compared with the AD subjects. Patients with DLB were more frequently affected with depression, stroke and cerebrovascular infarctions and migraine.

4.1 Medication
--------------

There were some interesting differences in the use of medication. Cholinesterase inhibitors were used in the majority of DLB and AD patients. Although these drugs are indicated for AD and Parkinson's disease with dementia, but not formally for DLB, there is good evidence that they are also useful in DLB \[[@B22]\],\[[@B23]\]. Memantine was prescribed for 15% of DLB patients and 10% of AD patients, although the evidence is less conclusive for DLB. However, there are some indications that memantine may in fact be useful also for DLB \[[@B24]\], including meta-analysis data \[[@B23]\].

4.2 Depression
--------------

Depression was more frequent in both men and women in the DLB group compared with AD, particularly in patients with a lower cognitive status at the time when dementia was diagnosed. Depression is a common feature of DLB \[[@B11]\], especially in its early stages. Several hypotheses have linked depression to the etiology and pathophysiology of dementia, depression may be a risk factor for DLB \[[@B9]\]. DLB has also been associated with a higher risk of depression \[[@B25]\]. The etiology of depression is probably multifactorial and the relation to dementia is complex. In our study, depression was significantly more often diagnosed in DLB patients before they were diagnosed with dementia. After the dementia diagnosis was set, depression occurrence did not differ between the DLB and AD patients.

It is a matter of dispute whether depression is a risk factor or a prodromal stage of DLB. Nonmotor symptoms and widespread brain pathological changes are believed to occur in DLB before dementia onset \[[@B26]\], so depression may be a sign of underlying pathological changes that are already present in DLB subjects. It would be of interest to investigate whether prevention or treatment of depression could decrease the incidence of DLB or postpone the development of dementia.

4.3 Migraine
------------

In our study, migraine was more common in the DLB group before dementia was diagnosed. Furthermore, it occurred more frequently in DLB patients that had a lower MMSE score at the time of diagnosis. Migraine was shown as a risk factor for developing dementia \[[@B27]\] and associated with smaller brain tissue volumes \[[@B28]\]. Recently, headache has been suggested as a risk factor for the development of vascular dementia in a prospective population-based study \[[@B29]\]. However, there are no previous studies investigating migraine in DLB patients. Conditions that are common in DLB patients and subjects suffering from migraine include complex visual hallucination \[[@B30]\] and disorders in olfactory perception \[[@B31]\]. Even though their etiology seems different, further research on these two disorders could provide valuable insights into the relationship between DLB and migraine.

4.4 Stroke
----------

Strokes were found to be more common for both men and women in the DLB group compared with the AD group, especially in subjects with lower MMSE scores. The occurrence of cerebrovascular infarctions but not cerebral hemorrhages after dementia diagnosis was significantly higher in the DLB group compared with AD patients. This relationship was not significant before dementia was diagnosed. This finding is surprising as strokes are common predictors for AD \[[@B32]\]. The difference in use of antipsychotics may be an explanation.

Studies on cerebrovascular pathology in DLB patients are not numerous and provide contradictory results. In a neuropathological study that included 96 DLB patients, no lesions of ischemic strokes were present in these subjects. The study suggested that the diagnosis of DLB had a protective effect against stroke \[[@B33]\]. Another study suggested that DLB patients with advanced typical Lewy body pathology were less likely to have history of stroke and cerebrovascular diseases \[[@B34]\]. This study revealed that infarcts, atherosclerosis and small vessel disease were inversely correlated to the extent of the DLB pathology. Nevertheless, cerebral amyloid angiopathy was associated with the grade of DLB pathology. A neuropathological case report revealed severe cerebral amyloid angiopathy in the presence of DLB pathology \[[@B35]\]. However, it can be argued that cerebral amyloid angiopathy is not related to DLB, but rather is a sign of pathological aging and concomitant AD \[[@B36]\],\[[@B37]\].

Even though the reasons are not clear, our study -- strengthened by a large sample size -- revealed a significantly frequent occurrence of stroke, specifically cerebral infarctions in DLB patients. More research is thus crucial to further elucidate this association. It can be speculated that the use of antipsychotics may have contributed to the development of strokes \[[@B38]\]. It is of interest that a considerable proportion of DLB patients were treated with antipsychotic medication before they were diagnosed with dementia (16%). This could be due to the clinical presentation of DLB, in which, in contrast to AD, frequent visual hallucinations are common early in the disease process.

Underlying psychiatric disorders may also be confounders \[[@B39]\] and lead to need for antipsychotics. It has been shown that antipsychotic treatment in dementia is associated with worse outcomes such as shorter time to nursing home admission, cerebrovascular events and mortality in older people \[[@B4]\],\[[@B40]\]-\[[@B42]\]. The Swedish guidelines for the treatment of neuropsychiatric symptoms in dementia therefore state that antipsychotics should be used very restrictively and only for psychotic symptoms or aggression that causes suffering or potential danger to the patient or others \[[@B20]\]. However, they are often prescribed to older people with dementia \[[@B43]\],\[[@B44]\], particularly in the nursing home setting \[[@B45]\],\[[@B46]\].

Cardiovascular comorbidities are frequent in all dementia disorders \[[@B47]\],\[[@B48]\] and belong to commonly reported causes of death \[[@B49]\]. In our study they have been found more common in the DLB group compared with AD, particularly in female patients, those who live in their own house and have a lower cognitive status at the beginning of the diagnostic process. A recent nationwide study in Sweden revealed that 60% of DLB patients were treated with cardiovascular medication, but the use of these drugs was lower in this group compared with AD \[[@B47]\]. However, this difference may be attributed to the fear of side effects in DLB patients; for example, side effects due to autonomic dysfunction. AD patients present the lowest mortality rate compared with other dementia disorders \[[@B7]\] and are therefore considered the healthiest group of dementia patients \[[@B50]\], even though there are some contradictory reports \[[@B51]\],\[[@B52]\]. Investigating comorbidities in patients with dementia can provide with valuable insights into dementia disorders and contribute to better understanding of their pathophysiology.

4.5 Limitations and strengths
-----------------------------

One may criticize that the study is limited by the validity of diagnoses. However, the validity of the Swedish National Patient Registry has been shown to be high for many diagnoses \[[@B53]\]. Nevertheless, the underestimation of comorbidities is inevitable since the Swedish National Patient Registry is based on outpatient or inpatient referrals and those with mild symptoms who did not seek medical help are not recorded. The validity of the data in SveDem has been assessed, especially in memory clinics. The data registered in memory clinics in a random sample of patients were in good agreement with medical records in a validation process \[[@B54]\]. Moreover, although we considered timing for the events, the probability of reverse causation is not completely omitted.

The validity of the diagnosis of dementia disorders has not been examined. It is necessary to acknowledge that the way of diagnosing both dementia types in SveDem reflects clinical practice in Sweden, and biomarkers such as dopamine transporter single-photon emission computed tomography is not available at all centers. Symptoms of DLB and AD overlap, which leads to difficulties in the diagnostic process. Autopsy diagnosis is currently not available but many patients are followed longitudinally, which probably improves diagnostic accuracy. Linking SveDem to autopsy records in future could help assess the accuracy of the clinical diagnoses.

Our study benefits from one of the largest samples of DLB patients in the world. Most of the previous studies have focused either on a single or a small number of comorbidities, while we compared the entire comorbidity profile. Using the exact date of registration for each comorbidity and dementia, we had access to the consecutive timing of the events in order to determine whether comorbidities occurred either before or after dementia diagnosis. Both SveDem and the Swedish National Patient Registry have just a minute proportion of missing values. The personal registration number makes it possible to follow each individual over time and to connect corresponding information from different registries in Sweden. The number of hospital stays with missing personal registration numbers in the inpatient registry was only 0.6% in 2006 \[[@B53]\].

5 Conclusions
=============

Our study indicated a worse comorbidity profile in DLB patients, with a higher prevalence of depression, stroke and migraine, compared with the AD population. Deeper knowledge about these differences among the DLB and AD groups is needed. Future studies could explore whether the presented associations are due to different mechanisms of these disorders as well as studying their influence on diagnostics and care.
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